Skip to main content

Table 1 Patient and tumor characteristics

From: Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Characteristic, N (%)

Arm A

N = 22

Arm B

N = 14

Arm C

N = 14

P value

Age at randomization

 18–39 years

2 (9)

5 (36)

1 (7)

 

 40–49 years

8 (36)

0

5 (36)

 

 50–59 years

5 (23)

4 (29)

7 (50)

 

 ≥ 60 years

7 (32)

5 (36)

1 (7)

0.02

Extent of surgery

 Breast sparing

9 (41)

6 (43)

6 (43)

 

 Mastectomy

13 (59)

8 (57)

8 (57)

0.99

Tumor size

 ≤ 2.0 cm

9 (41)

6 (43)

9 (64)

 

 2.1–4.9 cm

13 (59)

7 (50)

5 (36)

 

 ≥ 5.0 cm

0

1 (7%)

0

0.33

Axillary lymph node dissection

 Yes

20 (91)

14 (100)

14 (100)

 

 No

2 (9)

0

0

0.27

Sentinel node biopsy

 Yes

8 (36)

8 (57)

6 (43)

 

 No

14 (64)

6 (43)

8 (57)

0.47

Tumor grade

 Low/Intermediate

4 (18)

4 (29)

6 (43)

 

 High

18 (82)

10 (71)

8 (57)

0.28

T stage

 1

9 (41)

6 (43)

9 (64)

 

 2

13 (59)

7 (50)

5 (36)

 

 3

0

1 (7)

0

0.33

N stage

 1

21 (95)

13 (93)

14 (100)

 

 2

1 (5)

1 (7)

0

0.62